BACE Inhibitors and Tau Protein Targeting Drugs in Prevention of Alzheimer’s Disease

Alzheimer’s disease (AD) is a common disease in the United States with almost 10% of people older than 65 suffering from the disease. A few drugs provide some improvement in mental function in mild-to-moderate disease, but no treatments are available to prevent the development of AD. Two new classes of drugs being investigated for the treatment or prevention of AD include drugs to decrease beta amyloid accumulation and Tau protein aggregation inhibitors. After disappointing results for treatment of AD, both classes are being tested in prevention trials. (The full article is available in the December issue of Hospital Pharmacy) 

​Track investigational drugs and find out their current status in the Prescribe Right Pharmaceutical Pipeline Tracker